NICE has issued a final “no” to Bristol-Myers Squibb’s oral MS drug Zeposia (ozanimod), in a decision that prevents access for patients in England and Wales.

That potential is still all speculative, however, as BMS delayed the launch of Zeposia after its approval in MS in March as a result of the coronavirus pandemic, eventually making it available in ...

MS disease-modifying therapies (DMTs ... in your brain become swollen and narrowed may also occur. Mayzent and Zeposia are ...

Zeposia, an ulcerative colitis medication, ran Z The Light, a direct-to-consumer campaign aimed at driving awareness, intent to ask doctors for the brand, prescriptions and brand equity. Summary of ...